We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers submitting anonymous clinical data in applications to the European Medicines Agency must keep up on technology advances that could put that data at risk for re-identification.
The International Committee of Medical Journal Editors is seeking feedback on proposed requirements involving transparency for clinical trials authors as a condition for publication in member journals.